Trametinib Impurities

• No, trametinib is not classified as traditional chemotherapy.
• It is a targeted therapy that inhibits a specific enzyme (MEK1/2) in the MAPK/ERK pathway, which plays a key role in cancer cell growth and survival.
• Unlike chemotherapy, which kills rapidly dividing cells broadly, trametinib targets molecular mutations found in certain cancer cells.

Trametinib is used:

• Alone or in combination with dabrafenib to treat unresectable or metastatic melanoma
• After surgical removal of melanoma to reduce the risk of recurrence
• In cancers where the tumor has BRAF V600E or V600K mutations
• It may also be used in certain cases of non-small cell lung cancer (NSCLC) or anaplastic thyroid cancer, as guided by genetic testing

• No, trametinib is a MEK inhibitor, not a BRAF inhibitor.
• It works downstream of BRAF in the MAPK/ERK pathway.
• When used in combination with dabrafenib (a BRAF inhibitor), it helps provide a more complete blockade of the cancer-promoting pathway in BRAF-mutated tumors.

• Trametinib selectively inhibits MEK1 and MEK2, enzymes that are part of the RAS/RAF/MEK/ERK signaling cascade.
• This pathway is often overactive in cancers with BRAF mutations, leading to uncontrolled cell proliferation.
• By blocking MEK activity, trametinib reduces cell division and promotes cancer cell death in affected tumors.